New study sheds light on impact of fluvoxamine on COVID symptoms in certain cases

A randomized clinical trial of 1,175 participants found that treatment with higher-dose fluvoxamine did not improve time to sustained recovery in outpatients with mild to moderate COVID-19. The study compared fluvoxamine 100 mg twice daily for 13 days to placebo.

Researchers at Brigham and Women's Hospital found that people with wide-ranging long COVID symptoms were twice as likely to have SARS-CoV-2 proteins in their blood compared to those without long COVID symptoms. This persistent infection could explain some of the long COVID sufferers' symptoms, suggesting a potential treatment target.

European Centre for Disease Prevention and Control reports significant increase in STI cases across Europe, with gonorrhoea cases rising by 48%, syphilis cases by 34%, and chlamydia cases by 16%. The surge highlights the need for enhanced prevention, access to testing, and effective treatment to address this public health challenge.

A global research team has identified fluvoxamine as a medication that significantly improves fatigue and quality of life among adults with long COVID. The study found consistent and meaningful benefits from the widely available antidepressant.

A study of 144 Covid survivors found that women with elevated inflammatory biomarkers during the acute phase were more likely to experience lingering symptoms like fatigue, breathlessness, and sleep disturbance. This research sheds light on a potential link between inflammation and persistent Long Covid symptoms in women.

Research suggests that long COVID's impact on the health system is due to high volumes of COVID-19 cases rather than symptom severity. Symptoms reported with long COVID include fatigue, brain fog, and shortness of breath, but are indistinguishable from those experienced by individuals with seasonal influenza or other post-viral illnesses.